Search results
Results from the WOW.Com Content Network
This is a list of investigational autism and pervasive developmental disorder drugs, or drugs that are currently under development for clinical use in the treatment of autistic spectrum disorders and/or other pervasive developmental disorders but are not yet approved.
Interventions may include special education, psychiatric treatment, standard epilepsy treatment, audiology assessment, physical and occupational therapy for gross/fine motor skills, and regular monitoring of congenital anomalies or defects. Due to increased risk of obesity associated with the syndrome, psychiatric medications associated with ...
The use of technology has begun to be implemented in ABA therapy for the treatment of autism. [49] Robots, gamification, image processing, story boards, augmented reality, and web systems have been shown to be useful in the treatment of autism. [49] These technologies are used to teach children with autism skill acquisition. [49]
Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control excess body fat. These medications alter one of the fundamental processes of the human body , weight regulation, by: reducing appetite and consequently energy intake , increasing energy expenditure , redirecting nutrients from adipose to lean ...
As of 2023 there are several anti-obesity medications which are approved by the FDA for the treatment of obesity in adolescents. These medications are only recommended for use in conjunction with an intensive behavioral and lifestyle counselling program. [6] Orlistat is a lipase inhibitor which prevents the absorption of fats after meals. It is ...
This category is for medical conditions which can cause, follow from, be aggravated by, or correlate with obesity. Subcategories This category has the following 2 subcategories, out of 2 total.
The review found that CBT was moderately to highly effective at reducing anxiety in school children with autism spectrum disorder, but that effects varied depending on whether they were reported by clinicians, parents or self-reported. Treatments involving parents and one-on-one compared to group treatments were more effective. [15]
Psilocybin (PSY-0.1, PSY-0.2, PSY-0.3, PSY-0.4/0.5, PSY-0.6) – non-selective serotonin receptor agonist and psychedelic hallucinogen – substance-related disorders, neurological disorders, opioid-related disorders, psychiatric disorders, traumatic brain injury, cancer, anxiety disorders, bipolar disorders, depressive disorders, eating ...